SeaStar Medical to Present at the Virtual Emerging Growth Conference on June 12, 2024GlobeNewsWire • 06/06/24
Manuscript Published on Multiorgan Failure Patients Treated with SeaStar Medical's Selective Cytopheretic Device Who Achieved Transplant EligibilityGlobeNewsWire • 05/22/24
SeaStar Medical Announces $3.6 Million NIH Grant Award to Study the Selective Cytopheretic Device in Adult Patients with Severe Chronic Heart FailureGlobeNewsWire • 04/30/24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of SeaStar Medical Holding Corporation - ICUPRNewsWire • 04/28/24
SeaStar Medical Reports 2023 Financial Results and Provides a Business UpdateGlobeNewsWire • 04/17/24
SeaStar Medical to Present at the Noble Capital Markets' Emerging Growth Virtual Healthcare Equity ConferenceGlobeNewsWire • 04/11/24
SeaStar Medical to Restate Financials, Sets Business Update Call for April 17GlobeNewsWire • 03/27/24
SeaStar Medical Provides Updates on Enrollment of Adult Pivotal Clinical Study and Commercial Launch of Quelimmune, FDA-Approved in Pediatric PatientsGlobeNewsWire • 03/12/24
SeaStar Medical-Sponsored Symposium Featuring Experts Discussing Pediatric Acute Kidney Injury and the Selective Cytopheretic Device to be Webcast Live at AKI & CRRT 2024GlobeNewsWire • 03/11/24
Manuscript Discussing the Benefit of SeaStar Medical's Selective Cytopheretic Device in Patients with Heart Failure and Hyperinflammation Published in European Journal of Heart FailureGlobeNewsWire • 02/27/24
FDA Grants Humanitarian Device Exemption Approval to SeaStar Medical's Selective Cytopheretic Device for Pediatric Acute Kidney InjuryGlobeNewsWire • 02/22/24
SeaStar Medical Granted Canadian Patent with Broad Claims Covering the Selective Cytopheretic Device TechnologyGlobeNewsWire • 02/01/24
SeaStar Medical Announces Pricing of $9.0 Million Registered Direct Offering Priced At-the-MarketGlobeNewsWire • 01/26/24
SeaStar Medical Issued U.S. Patent with Broad Claims Covering Use of the Selective Cytopheretic Device for Multiple Clinical IndicationsGlobeNewsWire • 01/09/24
SeaStar Medical Updates Subject Enrollment in its Pivotal Trial with the Selective Cytopheretic Device in Adults with Acute Kidney InjuryGlobeNewsWire • 12/28/23
SeaStar Medical Forms Scientific Advisory Board of World-Renowned Pediatric and Adult Clinical ExpertsGlobeNewsWire • 12/13/23
SeaStar Medical Reports Third Quarter 2023 Financial Results and Provides a Business UpdateGlobeNewsWire • 11/14/23
FDA Issues Approvable Letter for SeaStar Medical's Selective Cytopheretic Device for Pediatric PatientsGlobeNewsWire • 10/30/23
SeaStar Medical's stock more than doubles in 2 days to get back above the $1 levelMarket Watch • 10/19/23